SecBot SecBot
8-K ·Filed May 4, 2026

APLS

Apellis Pharmaceuticals, Inc.
NEUTRAL
Impact 2/10
Horizonweeks Processed6mo ago SEC0001193125-26-202504
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

No immediate trading signal. Monitor the merger timeline and any regulatory or shareholder approvals for Biogen's acquisition of Apellis.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$40.97
T+0 close · May 4, 2026 · via day close
Latest settled
+0.12%
T+5 · $41.02
Vs SPY
−2.81%
α at T+5
Next horizon
T+20
due 6mo ago
  1. T+0 · May 4 $40.97entry
  2. T+1 · 7mo ago 0.00%α −0.80% · $40.97
  3. T+5 · 6mo ago +0.12%α −2.81% · $41.02
  4. T+20 · due 6mo ago Pending
  5. T+60 · due 4mo ago Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Apellis Pharmaceuticals amended its Executive Separation Benefits and Retention Plan in connection with its pending merger with Biogen. The amendment accelerates vesting of converted equity awards for named executive officers if terminated without cause or for good reason post-closing. This is a routine compensatory arrangement tied to the merger with no immediate financial impact or officer changes.

Key Facts

  • Compensation committee approved amendments to the Executive Separation Benefits and Retention Plan on April 28, 2026, effective upon closing of the Biogen merger.
  • Amendments accelerate vesting of converted options and RSUs for named executive officers upon termination without cause or resignation for good reason post-closing.
  • Good reason definition modified to exclude scope changes from becoming a subsidiary for C-level officers.

Financial Impact

No financial figures disclosed; immaterial relative to merger consideration.

Risk Factors

  • Merger closing risks (regulatory, shareholder approvals)
  • Potential executive retention issues post-merger

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
44% bullish (27 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-202504
Document: 0001193125-26-202504-index-headers.html0001193125-26-202504
Document: 0001193125-26-202504-index.html0001193125-26-202504
Document: 0001193125-26-202504.txt0001193125-26-202504

Track record

5 reports on APLS

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. May 26, 202624w ago 15-12G Neutral 6/10 No price data
  2. May 14, 202626w ago 25-NSE Neutral 2/10 Entry $41.03 to $41.03 · 0.00% +1.23% vs SPY
  3. May 14, 202626w ago 8-K Bullish 8/10 Entry $41.03 to $41.03 · 0.00% +1.23% vs SPY
  4. May 4, 202628w ago 8-K Neutral 2/10 Viewing Entry $40.97 to $40.97 · 0.00% −0.80% vs SPY
  5. Mar 27, 202633w ago Institutional Cluster Mixed 6/10 Entry $16.97 to $17.09 ▲ +0.71% +1.06% vs SPY
Showing 5 of 5

US Market Status

Market Closed · Opens Wed (11h 11m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 4, 2026